TY - JOUR
T1 - MicroRNA-1
T2 - Diverse role of a small player in multiple cancers
AU - Khan, Parvez
AU - Ebenezer, Nivetha Sarah
AU - Siddiqui, Jawed Akhtar
AU - Maurya, Shailendra Kumar
AU - Lakshmanan, Imayavaramban
AU - Salgia, Ravi
AU - Batra, Surinder Kumar
AU - Nasser, Mohd Wasim
N1 - Funding Information:
We thank our colleagues for their valuable suggestions, critical reading, and useful comments on this review. Our apology to colleagues for not citing their work in this review owing to space limitations. Figures were created using BioRender.com. Lung cancer studies in our laboratory are supported by the National Institutes of Health (NIH) grants R01CA218545 and R01CA241752 to MWN. The work of SKB is supported by NIH R01CA247471, R01CA195586, and P01 CA217798. The work of RS is supported by the National Cancer Institute of the NIH under award numbers P30CA033572, U54CA209978, R01CA247471, and R01CA218545. Interpretations, opinions, and conclusions presented in this manuscript are those of the authors and does not necessarily represent the official views of the National Institutes of Health and other funding agencies. PK, NSE, and MWN were involved in the conception and design of the review. PK and NSE researched the data for the article and wrote the original draft of the manuscript. PK and NSE contributed equally to this manuscript. PK, NE, JAS, SKM, IL, RS, SKB, and MWN critically revised the manuscript. All authors read and approved the content of the manuscript before final submission.
Funding Information:
We thank our colleagues for their valuable suggestions, critical reading, and useful comments on this review. Our apology to colleagues for not citing their work in this review owing to space limitations. Figures were created using BioRender.com. Lung cancer studies in our laboratory are supported by the National Institutes of Health (NIH) grants R01CA218545 and R01CA241752 to MWN. The work of SKB is supported by NIH R01CA247471 , R01CA195586 , and P01 CA217798 . The work of RS is supported by the National Cancer Institute of the NIH under award numbers P30CA033572 , U54CA209978 , R01CA247471 , and R01CA218545 . Interpretations, opinions, and conclusions presented in this manuscript are those of the authors and does not necessarily represent the official views of the National Institutes of Health and other funding agencies.
Publisher Copyright:
© 2021
PY - 2022/4
Y1 - 2022/4
N2 - The process of cancer initiation and development is a dynamic and complex mechanism involving multiple genetic and non-genetic variations. With the development of high throughput techniques like next-generation sequencing, the field of cancer biology extended beyond the protein-coding genes. It brought the functional role of noncoding RNAs into cancer-associated pathways. MicroRNAs (miRNAs) are one such class of noncoding RNAs regulating different cancer development aspects, including progression and metastasis. MicroRNA-1 (miR-1) is a highly conserved miRNA with a functional role in developing skeletal muscle precursor cells and cardiomyocytes and acts as a consistent tumor suppressor gene. In humans, two discrete genes, MIR-1–1 located on 20q13.333 and MIR-1–2 located on 18q11.2 loci encode for a single mature miR-1. Downregulation of miR-1 has been demonstrated in multiple cancers, including lung, breast, liver, prostate, colorectal, pancreatic, medulloblastoma, and gastric cancer. A vast number of studies have shown that miR-1 affects the hallmarks of cancer like proliferation, invasion and metastasis, apoptosis, angiogenesis, chemosensitization, and immune modulation. The potential therapeutic applications of miR-1 in multiple cancer pathways provide a novel platform for developing anticancer therapies. This review focuses on the different antitumorigenic and therapeutic aspects of miR-1, including how it regulates tumor development and associated immunomodulatory functions.
AB - The process of cancer initiation and development is a dynamic and complex mechanism involving multiple genetic and non-genetic variations. With the development of high throughput techniques like next-generation sequencing, the field of cancer biology extended beyond the protein-coding genes. It brought the functional role of noncoding RNAs into cancer-associated pathways. MicroRNAs (miRNAs) are one such class of noncoding RNAs regulating different cancer development aspects, including progression and metastasis. MicroRNA-1 (miR-1) is a highly conserved miRNA with a functional role in developing skeletal muscle precursor cells and cardiomyocytes and acts as a consistent tumor suppressor gene. In humans, two discrete genes, MIR-1–1 located on 20q13.333 and MIR-1–2 located on 18q11.2 loci encode for a single mature miR-1. Downregulation of miR-1 has been demonstrated in multiple cancers, including lung, breast, liver, prostate, colorectal, pancreatic, medulloblastoma, and gastric cancer. A vast number of studies have shown that miR-1 affects the hallmarks of cancer like proliferation, invasion and metastasis, apoptosis, angiogenesis, chemosensitization, and immune modulation. The potential therapeutic applications of miR-1 in multiple cancer pathways provide a novel platform for developing anticancer therapies. This review focuses on the different antitumorigenic and therapeutic aspects of miR-1, including how it regulates tumor development and associated immunomodulatory functions.
KW - Cancer therapeutics
KW - Chemosensitivity
KW - Immunoregulation
KW - MiR-1
KW - MiRNAs
UR - http://www.scopus.com/inward/record.url?scp=85107046931&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107046931&partnerID=8YFLogxK
U2 - 10.1016/j.semcdb.2021.05.020
DO - 10.1016/j.semcdb.2021.05.020
M3 - Review article
C2 - 34034986
AN - SCOPUS:85107046931
SN - 1084-9521
VL - 124
SP - 114
EP - 126
JO - Seminars in Cell Biology
JF - Seminars in Cell Biology
ER -